Obesity drugmaker Novo Nordisk's Q1 profit beats forecast
- Country:
- United Kingdom
Novo Nordisk posted on Thursday first-quarter operating profit above analyst forecasts, as the Danish drugmaker races to boost output of its hugely popular weight-loss drug Wegovy and fend off competition from Eli Lilly.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
Advertisement
ALSO READ
India's Cipla open to partnering with Eli Lilly to market their obesity drugs, CEO says
Health News Roundup: US FDA panel to discuss Eli Lilly Alzheimer's drug on June 10; Tylenol maker Kenvue to cut 4% jobs, beats quarterly profit estimates and more
Wegovy weight loss sustained for four years in trial, Novo Nordisk says
Wegovy weight loss sustained for four years in trial, Novo Nordisk says
Health News Roundup: Wegovy weight loss sustained for four years in trial, Novo Nordisk says; New breast cancer genes found in women of African ancestry, may improve risk assessment and more
Google News